Grant McArthur

Towards new models of cancer care in Australia: lessons from Victoria's response to theCOVID-19 pandemic

Craig Underhill, Phillip Parente, Grant McArthur, Andrew Haydon, Sue-Anne McLachlan, Zee Wan Wong, Eva Segelov

Journal article  |  2020  |  Internal Medicine Journal

In response to the COVID-19 pandemic, the Department of Health and Human Services Victoria (DHHS), the Monash Partners Comprehensi..

Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib /- cobimetinib: a pooled analysis of four clinical trials

Paolo A Ascierto, Antoni Ribas, James Larkin, Grant A McArthur, Karl D Lewis, Axel Hauschild, Keith T Flaherty, Edward McKenna, Qian Zhu, Yong Mun, Brigitte Dreno

Journal article  |  2020  |  Journal of Translational Medicine

BACKGROUND: We sought to identify patient subgroups with distinct postprogression overall survival (ppOS) outcomes and investigate..

Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade serous ovarian cancer.

Elaine Sanij, Katherine Hannan, Jiachen Xuan, Shunfei Yan, Jessica A Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe T Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J Wakefield, Sarah Ellis, Carleen Cullinane, Gretchen Poortinga, Kum Kum Khanna, Linda Mileshkin, Grant A McArthur, John Soong, Els M Berns, et al.

Journal article  |  2020  |  CLINICAL CANCER RESEARCH

Abstract High-grade serous ovarian cancer (HGSOC) accounts for the majority of ovarian cancer and has a dismal prognosis. PARP inh..

Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade serous ovarian cancer.

Elaine Sanij, Katherine Hannan, Jiachen Xuan, Shunfei Yan, Jessica A Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe T Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J Wakefield, Sarah Ellis, Carleen Cullinane, Gretchen Poortinga, Kum Kum Khanna, Linda Mileshkin, Grant A McArthur, John Soong, Els M Berns, et al.

Conference Proceedings  |  2020  |  CLINICAL CANCER RESEARCH

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

Ralf Gutzmer, Daniil Stroyakovskiy, Helen Gogas, Caroline Robert, Karl Lewis, Svetlana Protsenko, Rodrigo P Pereira, Thomas Eigentler, Piotr Rutkowski, Lev Demidov, Georgy Moiseevich Manikhas, Yibing Yan, Kuan-Chieh Huang, Anne Uyei, Virginia McNally, Grant A McArthur, Paolo A Ascierto

Journal article  |  2020  |  The Lancet

BACKGROUND: IMspire150 aimed to evaluate first-line combination treatment with BRAF plus MEK inhibitors and immune checkpoint ther..

Obesity and the Impact on Cutaneous Melanoma: Friend or Foe?

Lorey K Smith, Shaghayegh Arabi, Emily J Lelliott, Grant A McArthur, Karen E Sheppard

Journal article  |  2020  |  Cancers

Excess body weight has been identified as a risk factor for many types of cancers, and for the majority of cancers, it is associat..

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

Elaine Sanij, Katherine M Hannan, Jiachen Xuan, Shunfei Yan, Jessica E Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe T Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J Wakefield, Daniel Frank, Sarah Ellis, Carleen Cullinane, Jian Kang, Gretchen Poortinga, Purba Nag, Andrew J Deans, Kum Kum Khanna, et al.

Journal article  |  2020  |  NATURE COMMUNICATIONS

Acquired resistance to PARP inhibitors (PARPi) is a major challenge for the clinical management of high grade serous ovarian cance..

F-18-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma

Annie Wong, Jason Callahan, Marleen Keyaerts, Bart Neyns, Johanna Mangana, Susanne Aberle, Alan Herschtal, Sonia Fullerton, Donna Milne, Amir Iravani, Grant A McArthur, Rodney J Hicks

Journal article  |  2020  |  Cancer Imaging

BACKGROUND: Immune checkpoint blockade such as ipilimumab and anti-PD1 monoclonal antibodies have significantly improved survival ..

Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019

Selma Ugurel, Joachim Roehmel, Paolo A Ascierto, Jurgen C Becker, Keith T Flaherty, Jean J Grob, Axel Hauschild, James Larkin, Elisabeth Livingstone, Georgina Long, Paul Lorigan, Grant A McArthur, Antoni Ribas, Caroline Robert, Lisa Zimmer, Dirk Schadendorf, Claus Garbe

Journal article  |  2020  |  European Journal of Cancer

BACKGROUND: Recent therapeutic strategies, particularly MAP kinase pathway inhibitors (BRAF, MEK) and immune checkpoint blockers (..

Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma

Hsin-Yi Tseng, Jan Dreyer, Abdullah Al Emran, Dilini Gunatilake, Mehdi Pirozyan, Carleen Cullinane, Ken Dutton-Regester, Helen Rizos, Nicholas K Hayward, Grant McArthur, Peter Hersey, Jessamy Tiffen, Stuart Gallagher

Journal article  |  2020  |  International Journal of Cancer